# Tri Locum Partners LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1826434. Source: https://holderbook.com/funds/1826434-tri-locum-partners-lp/

- Reported value: $813.2M
- Positions: 19
- Weight of the ten largest: 80.0%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| JOHNSON & JOHNSON | [JNJ](https://holderbook.com/stocks/JNJ/) | $107.9M | 424,945 | 13.3% | 4 |
| VERTEX PHARMACEUTICALS INC | [VRTX](https://holderbook.com/stocks/VRTX/) | $100.2M | 201,791 | 12.3% | 2 |
| ELI LILLY & CO | [LLY](https://holderbook.com/stocks/LLY/) | $91.8M | 76,532 | 11.3% | 3 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $69.0M | 258,740 | 8.5% | 1 |
| DEXCOM INC | [DXCM](https://holderbook.com/stocks/DXCM/) | $55.3M | 820,479 | 6.8% | 3 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $53.7M | 219,308 | 6.6% | 15 |
| JAZZ PHARMACEUTICALS PLC | [JAZZ](https://holderbook.com/stocks/JAZZ/) | $53.4M | 221,720 | 6.6% | 2 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $44.0M | 866,716 | 5.4% | 1 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $38.6M | 41,596 | 4.7% | 12 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $36.7M | 68,273 | 4.5% | 15 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $28.4M | 151,822 | 3.5% | 1 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $25.5M | 47,026 | 3.1% | 4 |
| TEVA PHARMACEUTICAL INDS LTD | [TEVA](https://holderbook.com/stocks/TEVA/) | $25.3M | 746,835 | 3.1% | 3 |
| TARSUS PHARMACEUTICALS INC | [TARS](https://holderbook.com/stocks/TARS/) | $20.7M | 328,340 | 2.5% | 2 |
| INTUITIVE SURGICAL INC | [ISRG](https://holderbook.com/stocks/ISRG/) | $19.1M | 47,983 | 2.3% | 2 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $16.5M | 194,000 | 2.0% | 1 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $11.8M | 120,712 | 1.4% | 4 |
| BETA BIONICS INC | [BBNX](https://holderbook.com/stocks/BBNX/) | $7.7M | 493,344 | 1.0% | 1 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $7.7M | 162,996 | 0.9% | 2 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +9.8% | +14.8% | -5.0% | 100% |
| Q1 2026 | +0.1% | -4.6% | +4.7% | 100% |
| Q4 2025 | +19.6% | +2.4% | +17.2% | 100% |
| Q3 2025 | +17.9% | +7.8% | +10.1% | 99% |
| Q2 2025 | +4.8% | +10.5% | -5.6% | 100% |
| Q1 2025 | -5.6% | -4.6% | -1.0% | 100% |
| Q4 2024 | +2.7% | +2.1% | +0.6% | 100% |
| Q3 2024 | +9.7% | +5.4% | +4.3% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $813.2M | 19 |
| Q1 2026 | $712.5M | 17 |
| Q4 2025 | $770.1M | 15 |
| Q3 2025 | $435.1M | 18 |
| Q2 2025 | $329.5M | 23 |
| Q1 2025 | $194.9M | 22 |
| Q4 2024 | $482.7M | 28 |
| Q3 2024 | $417.4M | 20 |
| Q2 2024 | $395.5M | 25 |
| Q1 2024 | $288.4M | 27 |
| Q4 2023 | $218.8M | 24 |
| Q3 2023 | $312.8M | 61 |